Trial Profile
A Single-Center Study to Evaluate the Safety and Tolerability of Hemoglobin-Based Oxygen Carrier-201 (HBOC 201) in Trauma Subjects. (Phase II - Safety and Tolerability)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Hemoglobin glutamer (Primary)
- Indications Haemorrhagic shock
- Focus Adverse reactions
- Sponsors HbO2 Therapeutics
- 12 May 2014 New trial record